DOA
CRSP icon

D'Orazio & Associates’s CRISPR Therapeutics CRSP Stock Holding History

D'Orazio & Associates’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-132
Closed -$8K – 282
2018
Q2 		$8K Hold
132
– – ﹤0.01% 210
2018
Q1 		$6K Hold
132
– – ﹤0.01% 226
2017
Q4 		$3K Buy
+132
New +$2.51K ﹤0.01% 284

Other funds holding CRSP

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

D'Orazio & Associates's CRSP Position: Q3 2018 in Review

D'Orazio & Associates sold out of CRISPR Therapeutics (CRSP) in Q3 2018, closing a stake of 132 shares — an estimated $8K sold.

D'Orazio & Associates first reported a position in CRSP in Q4 2017 and held it in 3 quarters. The position peaked at $8K in Q2 2018. 179 funds tracked by Wall St. Rank hold CRSP as of Q3 2018.

  • D'Orazio & Associates reported no remaining CRISPR Therapeutics position as of Q3 2018 after selling out during the quarter.
  • D'Orazio & Associates sold 132 CRISPR Therapeutics shares in Q3 2018, an estimated $8K.
  • D'Orazio & Associates first reported a position in CRISPR Therapeutics in Q4 2017 and held it in 3 quarters.
  • D'Orazio & Associates's CRISPR Therapeutics position peaked at $8K in Q2 2018.
  • 179 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2018.

Based on D'Orazio & Associates's 13F filing for Q3 2018, filed 13 Nov 2018.